A plain-language guide

Lambert-Eaton myasthenic syndrome

What's known, what's still uncertain, and what's actively debated, written plainly, and built only from published medical research.

Growing map · 35 sourced statements Every statement names its source Updated 2026-08-04
Please read this first. This guide is a companion to your medical team, not a replacement, and it is not medical advice. Everything here is tied to published research. If something you expected is not here, it almost always means we have not mapped a source for it yet, not that it is unknown to medicine. Lambert-Eaton myasthenic syndrome is an early, growing map, so it will look incomplete on purpose: we would rather show less and have every line be something you can check than fill the page with claims we cannot stand behind. For anything about your own situation, your clinicians hold the full picture. How this guide is built and why.

What's Lambert-Eaton myasthenic syndrome?

Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder of the neuromuscular junction in which antibodies against presynaptic voltage-gated calcium channels reduce acetylcholine release, producing proximal weakness, reduced reflexes, and autonomic symptoms. About half of cases are paraneoplastic, most often linked to small cell lung cancer. A distinctive feature is that strength and reflexes briefly improve right after exercise (post-exercise facilitation), which separates it from myasthenia gravis.

Also indexed asORPHA:43393, MONDO:0018556
Features mapped14
Treatments mapped6
Published sources9
Last reviewed2026-08-04

Signs and symptoms

Small cell lung carcinoma

About half of cases are paraneoplastic, meaning they are driven by a hidden cancer, most often small cell lung cancer. Because of this, a diagnosis prompts a careful search for an underlying tumour, often repeated over time.

Limited evidenceSource: PMID:42053006
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:40675738, ORPHA:43393
Notesplain_language confirmed from PMID:40675738 via curation 2026-06-14. | regrounded primary ORPHA:43393 -> PMID:42053006 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Anti-P/Q-type VGCC antibody positivity

Most people have antibodies against the P/Q-type voltage-gated calcium channel. These channels normally let the nerve ending release acetylcholine, so blocking them is what weakens the signal to muscle. The antibody test is a key confirming finding.

Limited evidenceSource: PMID:41700072
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:41338910, ORPHA:43393
Notesplain_language confirmed from PMID:41338910 via curation 2026-06-14. | regrounded primary ORPHA:43393 -> PMID:41700072 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Calcium channel antibody positivity

Most people with Lambert-Eaton myasthenic syndrome have antibodies against voltage-gated calcium channels (VGCC) on nerve endings, which disrupt the release of the signal that tells muscle to contract. A blood test for these antibodies supports the diagnosis.

Limited evidenceSource: PMID:40675738
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:18342060, ORPHA:43393
Notesplain_language confirmed from PMID:18342060 via curation 2026-06-18 [carrie (curation)]. | regrounded primary ORPHA:43393 -> PMID:40675738 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Bulbar signs

Bulbar signs — problems with speech and swallowing from weakness of the muscles of the mouth and throat — can occur in Lambert-Eaton myasthenic syndrome, but they tend to appear later in the course and usually in severe, advanced cases rather than at the start.

Limited evidenceSource: PMID:40574941
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesORPHA:43393
Notesplain_language confirmed from PMID:40574941 via curation 2026-06-25 [claude-draft]. | regrounded primary ORPHA:43393 -> PMID:40574941 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Diminished deep tendon reflex

Tendon reflexes (such as the knee-jerk) are reduced or absent. A telling feature is that these reflexes can briefly return or strengthen for a few seconds right after the muscle is exercised.

Limited evidenceSource: PMID:42053006
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesORPHA:43393
Notesplain_language confirmed from PMID:42053006 via curation 2026-06-14. | regrounded primary ORPHA:43393 -> PMID:42053006 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Abnormal autonomic nervous system physiology

Many people with Lambert-Eaton myasthenic syndrome have autonomic nervous system dysfunction, because the same antibodies that weaken muscle also disrupt the nerves controlling automatic body functions. This can cause dry mouth, constipation, blurred vision, reduced sweating, and lightheadedness on standing.

Limited evidenceSource: PMID:24481713
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesORPHA:43393
Notesplain_language confirmed from PMID:24481713 via curation 2026-06-18 [carrie (curation)]. | regrounded primary ORPHA:43393 -> PMID:24481713 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Impotence

Other autonomic symptoms include erectile dysfunction (impotence), changes in sweating, and a drop in blood pressure on standing.

Limited evidenceSource: PMID:40544116
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesORPHA:43393
Notesplain_language confirmed from PMID:40544116 via curation 2026-06-14. | regrounded primary ORPHA:43393 -> PMID:40544116 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Orthostatic hypotension due to autonomic dysfunction

A drop in blood pressure on standing (orthostatic hypotension) can cause dizziness or faintness, and is part of the autonomic dysfunction seen in Lambert-Eaton myasthenic syndrome.

Limited evidenceSource: PMID:24481713
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesORPHA:43393
Notesplain_language confirmed from PMID:24481713 via curation 2026-06-18 [carrie (curation)]. | regrounded primary ORPHA:43393 -> PMID:24481713 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Constipation

Constipation is one of the autonomic symptoms of Lambert-Eaton myasthenic syndrome, reflecting the antibodies' effect on nerve signaling beyond the muscles.

Limited evidenceSource: PMID:24481713
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesORPHA:43393
Notesplain_language confirmed from PMID:24481713 via curation 2026-06-18 [carrie (curation)]. | regrounded primary ORPHA:43393 -> PMID:24481713 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Abnormality of the orbital region

Eye-related symptoms can occur in Lambert-Eaton myasthenic syndrome, including ptosis (a drooping eyelid) and diplopia (double vision). These ocular symptoms can accompany the leg weakness and autonomic features such as a dry mouth.

Limited evidenceSource: PMID:41700072
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesORPHA:43393
Notesplain_language confirmed from PMID:41700072 via curation 2026-06-25 [claude-draft]. | regrounded primary ORPHA:43393 -> PMID:41700072 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Xerostomia

Autonomic nerves are affected too. The most common autonomic symptom is a dry mouth, caused by reduced acetylcholine release at those nerves.

Limited evidenceSource: PMID:24481713
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:40544116, ORPHA:43393
Notesplain_language confirmed from PMID:40544116 via curation 2026-06-14. | regrounded primary ORPHA:43393 -> PMID:24481713 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Progressive proximal muscle weakness

The core symptom is gradually worsening weakness in the muscles closest to the trunk, especially the legs, so that walking, climbing stairs, and rising from a chair become difficult.

Limited evidenceSource: PMID:40574941
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesORPHA:43393
Notesplain_language confirmed from PMID:40574941 via curation 2026-06-14. | regrounded primary ORPHA:43393 -> PMID:40574941 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

EMG: repetitive nerve stimulation abnormality

Nerve testing is central to diagnosis. At rest the muscle response is small, but it grows markedly right after brief exercise or with rapid (high-frequency) repetitive nerve stimulation, while slow stimulation shows a decrement. This pattern of post-exercise facilitation is the electrical signature that distinguishes the condition.

Limited evidenceSource: PMID:40675738
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesORPHA:43393
Notesplain_language confirmed from PMID:40675738 via curation 2026-06-14. | regrounded primary ORPHA:43393 -> PMID:40675738 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

Hypohidrosis

Reduced sweating (hypohidrosis) can occur in Lambert-Eaton myasthenic syndrome as part of its autonomic involvement.

Limited evidenceSource: PMID:24481713
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesORPHA:43393
Notesplain_language confirmed from PMID:24481713 via curation 2026-06-18 [carrie (curation)]. | regrounded primary ORPHA:43393 -> PMID:24481713 on 2026-06-26 [Carrie Schluter, BCPA]
Last reviewed2026-06-26

How it is diagnosed

Lambert-Eaton myasthenic syndrome

Diagnosed using: Voltage-gated calcium channel antibody testing.

Limited evidenceSource: PMID:40675738
The source text this rests on
“…antibodies to voltage gated calcium channels are present in the majority of…”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:40675738 via curation 2026-06-25
Last reviewed2026-06-25

Lambert-Eaton myasthenic syndrome

Diagnosed using: Screening for underlying small-cell lung cancer.

Limited evidenceSource: PMID:40675738
The source text this rests on
“LEMS is associated with small cell lung cancer (SCLC), or rarely other tumours, in approximately 50 % of cases, for which patients should be carefully…”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:40675738 via curation 2026-06-25
Last reviewed2026-06-25

Lambert-Eaton myasthenic syndrome

Diagnosed using: Repetitive nerve stimulation.

Limited evidenceSource: PMID:40675738
The source text this rests on
“Typical electrophysiological findings include small compound muscle action potentials at rest that augment following short exercise, decrement at low…”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:40675738 via curation 2026-06-25
Last reviewed2026-06-25

Treatment and management

What the research describes, not a recommendation. Treatment decisions belong with your clinician.

This covers treatments that appear in the published research mapped here. Investigational and experimental therapies are not included, so their absence is a boundary of this map, not a sign they do not exist.

amifampridine

Amifampridine (3,4-diaminopyridine) is the first-line symptomatic treatment. It blocks potassium channels in the nerve ending, which prolongs the signal and lets more acetylcholine be released, improving strength.

Used to help with: Lambert-Eaton myasthenic syndrome.

Limited evidenceSource: PMID:41945880
The source text this rests on
“Amifampridine, a short-acting potassium-channel blocker, is the first-line treatment for Lambert-Eaton myasthenic syndrome.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:41945880 via curation 2026-06-14
Last reviewed2026-06-14

pyridostigmine

Pyridostigmine, which slows the breakdown of acetylcholine, can be added to help strengthen the nerve-to-muscle signal, often alongside other treatments.

Used to help with: Lambert-Eaton myasthenic syndrome.

Limited evidenceSource: PMID:42053006
The source text this rests on
“…combined with pyridostigmine led to marked neurological…”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:42053006 via curation 2026-06-14
Last reviewed2026-06-14

intravenous immunoglobulin

When symptoms are severe or do not respond to symptomatic drugs, immune treatments such as intravenous immunoglobulin (IVIG) can reduce the harmful antibodies and improve strength. Plasma exchange and immunosuppressants are used similarly.

Used to help with: Lambert-Eaton myasthenic syndrome.

Limited evidenceSource: PMID:40574941
The source text this rests on
“…four doses of intravenous immunoglobulin…”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:40574941 via curation 2026-06-14
Last reviewed2026-06-14

prednisone

When Lambert-Eaton myasthenic syndrome is not caused by a tumour, the corticosteroid prednisone — alone or together with other immune-suppressing medicines — is one of the treatment options. It works by calming the immune attack on the nerve ending rather than by easing symptoms directly.

Used to help with: Lambert-Eaton myasthenic syndrome.

Limited evidenceSource: PMID:22277398
The source text this rests on
“In non-paraneoplastic LEMS, prednisone alone or combined with immunosuppressants are treatment…”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:22277398 via curation 2026-06-25
Last reviewed2026-06-25

plasma exchange

When weakness is severe, plasma exchange — a procedure that filters the harmful antibodies out of the blood — can give short-term benefit in Lambert-Eaton myasthenic syndrome. It is used much like intravenous immunoglobulin in this situation.

Used to help with: Lambert-Eaton myasthenic syndrome.

Limited evidenceSource: PMID:22277398
The source text this rests on
“In both MG and LEMS, where weakness is severe, plasma exchange or intravenous immunoglobulin treatment may provide short-term…”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:22277398 via curation 2026-06-25
Last reviewed2026-06-25

treatment of underlying tumour

When Lambert-Eaton myasthenic syndrome is driven by a hidden cancer (paraneoplastic LEMS), treating that tumour often improves the neurological symptoms. This is why finding and treating an underlying cancer is a central part of care in these cases.

Used to help with: Lambert-Eaton myasthenic syndrome.

Limited evidenceSource: PMID:22277398
The source text this rests on
“In paraneoplastic LEMS, treatment of the tumor often results in neurological…”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:22277398 via curation 2026-06-25
Last reviewed2026-06-25

How to read the evidence labels

Widely acceptedSpecialists broadly agree on this.
Strong evidenceBacked by solid, repeated research.
Moderate evidenceReasonable evidence, still being confirmed.
Limited evidenceSome evidence, but not yet convincing.
Early evidenceAn early finding that needs more study.
Experts disagreeResearchers actively disagree about this.
No longer supportedLater, stronger evidence or guidance overturned this.

Where this comes from

This guide is built from 9 published source(s). Every claim above links back to one of them. Click any source ID to read the original on PubMed.

ORPHA:43393 · Orphanet/HPO annotations for Lambert-Eaton myasthenic syndrome
PMID:22277398 · [The pathophysiology and treatment of autoimmune neuromuscular junction diseases].
PMID:24481713 · Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management.
PMID:40544116 · The recognition, physiology, and treatment of Lambert-Eaton myasthenic syndrome.
PMID:40574941 · A Rare Case of Lambert-Eaton Myasthenia Syndrome With Dysphasia and Dysarthria.
PMID:40675738 · Lambert Eaton Myasthenic Syndrome.
PMID:41700072 · [How to Diagnose Lambert-Eaton Myasthenic Syndrome Patients Early: A Systematic Review of Japanese Case Reports].
PMID:41945880 · Efficacy and Safety of Amifampridine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Tria
PMID:42053006 · Lambert-Eaton Myasthenic Syndrome During Immunotherapy in Extensive-Stage Small-Cell Lung Cancer: A Case Report.

Take it further

Printed, source-linked documents built from this condition's graph — ready to bring to an appointment or attach to a coverage request. Every claim carries its published source, the same as this guide.